Tirzepatide With Crohn’s or Colitis: The 2026 Evidence

A September 2026 study provides a reason to investigate tirzepatide in people who also have inflammatory bowel disease, but it does not establish tirzepatide as a treatment for Crohn’s disease or ulcerative colitis. The research compared outcomes among people already prescribed tirzepatide or another GLP-1 medicine; it did not randomly assign an IBD treatment.¹

If you have IBD and are considering tirzepatide for an established metabolic indication, bring both treatment plans to your gastroenterologist and prescriber. Do not stop an effective IBD medicine because a weight-treatment study sounds promising.

What the new study found

The U.S. retrospective database study matched 3,042 adults with IBD in each treatment group and assessed outcomes over 18 months. Tirzepatide was associated with lower intravenous-steroid use than other GLP-1 medicines, with an adjusted hazard ratio of 0.81. Risks of hospitalization, emergency visits and intestinal surgery were similar between groups.¹

This is an association. Matching measured characteristics helps comparisons, but it cannot remove every difference between patients or prescribing decisions. The authors call for prospective studies. Do not translate the steroid result into an “IBD remission rate” or a guarantee about flare prevention.¹

Why symptoms need a shared plan

Nausea, diarrhea, constipation and abdominal discomfort can occur during tirzepatide treatment. In someone with IBD, a new digestive symptom should not automatically be assigned to the injection or automatically labeled a flare. The prescriber and GI team need to decide how it will be assessed.²

Agree on what to report, which team to contact first and which symptoms require urgent evaluation. A symptom diary can record injection timing, dose changes, bowel changes and medication adjustments without pretending that timing alone proves the cause.

Crohn’s disease is not the same as gastroparesis

A study involving inflammatory bowel disease does not answer every question about gastrointestinal conditions. The Zepbound label specifically says it is not recommended in severe gastroparesis. Prior obstruction, digestive surgery, current disease activity and nutritional problems each deserve their own review rather than a blanket “GI-safe” conclusion.²

Our gastroparesis and ileus guide explains that separate issue. The diarrhea guide covers another symptom pathway, but it is not a replacement for your IBD flare instructions.

Questions before starting or escalating

Ask whether the IBD is currently stable, how hydration and nutrition will be monitored, and whether any planned procedure changes the timing conversation. Provide the complete medication list, including oral medicines and any recent steroid course. Tirzepatide delays gastric emptying and can affect oral-drug absorption, so medicine-specific questions belong with the treating professionals.²

If treatment is already underway, discuss what changed after a dose increase and whether symptoms are limiting fluid or food intake. Do not increase the dose simply because the calendar permits it if your care team has not addressed a clinically important problem.

How to use this evidence

For an adult who otherwise needs tirzepatide, the study can inform a balanced discussion about the available observational experience in IBD. It cannot establish the best IBD drug, replace a disease-specific guideline or prove the same result in every person with Crohn’s disease or colitis.

Keep the indication clear. The approved Zepbound uses are weight reduction and maintenance in eligible adults and moderate-to-severe obstructive sleep apnea in adults with obesity—not IBD.² Our evidence guide separates approved uses from developing research so a promising study is not mistaken for a new approval.